Antibiotic resistance now kills more people worldwide than HIV or malaria. In February 2026, researchers at the University of California San Diego published a system in the journal npj Antimicrobials and Resistance that takes an unusual approach: rather than killing resistant bacteria, the CRISPR system called pPro-MobV cuts resistance genes from entire bacterial populations while spreading from cell to cell like a genetic virus, turning bacteria's own defenses against them.
What Is Antibiotic Resistance?
Approximately 1.27 million people died directly from antibiotic-resistant bacterial infections worldwide in 2019, according to a 2022 study published in The Lancet by the Global Burden of Antimicrobial Resistance research consortium. This kills more people than HIV (860,000) or malaria (640,000) in the same year. A 2024 Lancet analysis estimates that without new countermeasures, more than 39 million people could die from resistant infections by 2050.
The fundamental problem lies in biology. Antibiotics kill susceptible bacteria, but individuals with resistance genes survive and reproduce. The critical weakness: resistance genes often reside not on the bacteria's main chromosome but on small circular DNA fragments called plasmids. Through a process called horizontal gene transfer, plasmids can move between bacteria, even across species. A pathogen that is manageable today can acquire resistance within hours.
How pPro-MobV Spreads Through Bacteria
The system, developed by professors Ethan Bier and Justin Meyer, exploits this plasmid exchange. Bacteria form tiny channels when contacting each other, through which they exchange genetic information in a process called conjugation. Scientists have understood bacterial conjugation for decades. Bier and Meyer repurposed it as the delivery mechanism for a CRISPR cassette.
The mechanism works like this: the CRISPR cassette is introduced into a few bacteria. It precisely cuts antibiotic resistance genes on plasmids, copies itself, and travels through the conjugation channel into neighboring bacteria. There it cuts again, copies again, travels on. Gradually, more and more bacteria in the population lack resistance genes. The team published the system as "A conjugal gene drive-like system efficiently suppresses antibiotic resistance in a bacterial population." The term gene drive comes from insect research, where similar technologies reprogram mosquito populations to combat malaria. pPro-MobV is the first comparable system for bacteria.
The team also built in an emergency shutoff: a mechanism called homology-based deletion allows the CRISPR cassette to be removed from the system if necessary.
How pPro-MobV Differs from Earlier Approaches
CRISPR in bacteria has been a research focus since around 2015. The classical approach: CRISPR is delivered as a bacteriophage, a virus that infects bacteria. Phages are highly specific and typically kill infected bacteria. pPro-MobV does not kill. It reprograms. This matters for two reasons: first, reprogrammed bacteria retain normal function as part of the microbiome. Eliminating an entire bacterial species would be undesirable in many clinical contexts because it could harm beneficial microbes. Second, the system spreads through conjugation, not phage infection. Conjugation works across species boundaries, meaning pPro-MobV could theoretically treat multiple species simultaneously.
The research team identifies three possible applications: clinical medicine (multidrug-resistant hospital pathogens like MRSA, which killed over 100,000 people globally in 2019), environmental remediation (contaminated water where resistant bacteria from agriculture or wastewater persist), and microbiome engineering (targeted modification of bacterial communities in the gut without broad antibiotic use).
In Context: How Research Has Fought Superbugs
The antibiotic pipeline has largely dried up since the 1980s: almost no new antibiotic classes have been developed because profit margins are too low for pharmaceutical industry. Bacteriophage therapy has gained attention as an alternative. Phages are viruses that infect bacteria and were therapeutically used in the 1920s before antibiotics dominated medicine. The drawback: a phage typically works against only one bacterial strain. Clinical use requires libraries of hundreds of different phages.
A second approach involves antivirulence strategies: instead of killing bacteria, researchers block their ability to infect or form biofilms. Research groups at ETH Zurich and the University of Hamburg are working on such molecules, so far without clinical approval. Gene drives in insects as a third comparison: the British Target Malaria consortium attempts to alter Anopheles mosquito populations through gene drives to reduce malaria. The technology is related, the biological context different. pPro-MobV transfers the gene-drive concept for the first time from eukaryotic organisms (insects) to prokaryotes (bacteria), a distinct technical achievement given fundamentally different cell biology.
From Petri Dish to Patient: Years of Development Ahead
The system has been tested in laboratory bacterial cultures. Clinical use requires animal trials, then clinical studies in phases 1 through 3, and finally regulatory approval. Research foundations for Pro-Active Genetics began in 2019 through collaboration between Bier's lab and the team of infectious disease specialist Victor Nizet at UC San Diego School of Medicine, showing clinical relevance was considered from the start. The team provides no concrete timeline for clinical trials.
Key open questions remain: how does pPro-MobV behave in mixed populations with many bacterial species? How does it interact with the human host's immune responses? Does it completely eliminate resistance genes or only partially? These questions can only be answered through animal models and ultimately in humans. The combination of laboratory efficacy, built-in emergency shutoff, and three potential applications makes pPro-MobV one of the most unusual approaches in antibiotic resistance research in recent years, even though the path to clinical use remains long.